

# DROPERIDOL (Inapsine)

## EMSAM JULY 2025

### ACTION: Butyrophenone

- Droperidol produces a dopaminergic blockage, a mild alpha-adrenergic blockage, and causes peripheral vasodilation
- Onset of Action: 3 to 10 minutes after IM administration
- Duration: 2-3 hours

**INDICATIONS:** First line medication for severely agitated patients who pose serious probable and imminent bodily harm to self/others

### CONTRAINDICATIONS:

- Suspected acute myocardial infarction/acute coronary syndrome
- Hypotension (systolic blood pressure under 100mgHg, or the absence of a palpable radial pulse)
- Pregnancy
- Dementia related psychosis
- Patients < 18 years

### POTENTIAL SIDE EFFECTS

- Transient hypotension
- Dystonic reaction
- Extra-pyramidal reactions
- Sedation

### ADULT DOSE:

5mg Intramuscular X 1

### PEDIATRIC DOSE:

N/A

### NOTES:

- Caution use in patients >60 years of age
- May cause prolonged QT interval. Caution in patients with known prolonged QT syndrome or recent simultaneous use of other QT-prolonging drugs.
- All patients receiving droperidol should be placed on cardiac monitoring and EtCO<sub>2</sub> monitoring. Although obtaining an ECG on the combative or agitated patient may be difficult, an should be made to do so.
- Avoid patients known to be pregnant, regardless of gestational age
- Contact Base Hospital if additional doses of droperidol or midazolam are needed for patients with continued agitation after first dose of triperidol.